Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

被引：10
|
作者：
Kondagunta, GV
Bacik, J
Schwartz, L
Sheinfeld, J
Bajorin, D
Vuky, J
Marion, S
Mazumdar, M
Bosl, GJ
Motzer, RJ
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, New York, NY 10021 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2004年 / 22卷 / 02期
关键词：
temozolomide; germ cell tumor; nonseminoma; cisplatin-refractory; phase II;
D O I：
10.1023/B:DRUG.0000011794.21608.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m(2)/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
引用
收藏
页码：177 / 179
页数：3
相关论文
共 50 条
  • [1] Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors
    G. Varuni Kondagunta
    Jennifer Bacik
    Lawrence Schwartz
    Joel Sheinfeld
    Dean Bajorin
    Jacqueline Vuky
    Stephanie Marion
    Madhu Mazumdar
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2004, 22 : 177 - 179
  • [2] Phase II Trial of Pyrazoloacridine in Patients with Cisplatin-Refractory Germ Cell Tumors
    Jacqueline Vuky
    John McCaffrey
    Michelle Ginsberg
    Tania Mariani
    Dean F. Bajorin
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2000, 18 : 265 - 267
  • [3] Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors
    Vuky, J
    McCaffrey, J
    Ginsberg, M
    Mariani, T
    Bajorin, DF
    Bosl, GJ
    Motzer, RJ
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) : 265 - 267
  • [4] PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITH CISPLATIN-REFRACTORY GERM-CELL TUMORS
    PUC, HS
    BAJORIN, DF
    BOSL, GJ
    AMSTERDAM, A
    MOTZER, RJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (02) : 163 - 165
  • [5] An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors
    Oechsle, Karin
    Honecker, Friedemann
    Kollmannsberger, Christian
    Rick, Oliver
    Gruenwald, Victor
    Mayer, Frank
    Hartmann, Joerg T.
    Bokemeyer, Carsten
    ANTI-CANCER DRUGS, 2007, 18 (03) : 273 - 276
  • [6] Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors
    Oechsle, Karin
    Bokemeyer, Carsten
    Honecker, Friedemann
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (01) : 165 - 167
  • [7] Treatment of patients with cisplatin-refractory germ cell tumors
    Koychev, D.
    Honecker, F.
    Bokemeyer, C.
    Albers, P.
    ONKOLOGE, 2013, 19 (07): : 564 - 567
  • [8] Treatment of patients with cisplatin-refractory germ cell tumors
    Koychev, D.
    Honecker, F.
    Bokemeyer, C.
    Albers, P.
    ONKOLOGE, 2013, 19 (07): : 564 - 567
  • [9] Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors
    Karin Oechsle
    Carsten Bokemeyer
    Friedemann Honecker
    Journal of Cancer Research and Clinical Oncology, 2010, 136
  • [10] Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor
    De Giorgi, Ugo
    Rosti, Giovanni
    Aieta, Michele
    Testore, Franco
    Burattini, Luciano
    Fornarini, Giuseppe
    Naglieri, Emanuele
    Lo Re, Giovanni
    Zumaglini, Federica
    Marangolo, Maurizio
    EUROPEAN UROLOGY, 2006, 50 (05) : 1032 - 1039
12345